U.S. Markets closed

Medigene AG (MDGEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.24500.0000 (0.00%)
At close: 9:39AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.2450
Open4.2450
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.2450 - 4.2450
52 Week Range3.8000 - 7.6099
Volume51
Avg. Volume122
Market Cap110.193M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.7590
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers

    Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has received approval from the Dutch regulatory authority (the Central Committee on Research Involving Human Subjects, CCMO) to begin a first clinical trial of MDG1021. MDG1021, which targets the antigen HA-1, thus becomes Medigene’s second proprietary T cell receptor-modified T cell (TCR-T) immunotherapy candidate to enter clinical development.

  • GlobeNewswire

    Medigene’s PD1-41BB Switch Receptor Enhances TCR-T Cell Activity Towards Solid Tumors

    MARTINSRIED, Germany and MUNICH, Germany, June 22, 2020 -- Medigene AG (Medigene, FSE: MDG1), a clinical stage immuno-oncology company focusing on the development of T cell.

  • PHIO: Intasyl Advantage vs. Gene Editing
    Zacks Small Cap Research

    PHIO: Intasyl Advantage vs. Gene Editing

    By John Vandermosten, CFA NASDAQ:PHIO READ THE FULL PHIO RESEARCH REPORT Milestones: ‣ Partnership/Sale of Dermatology and Ophthalmology Programs – TBD ‣ Expansion of collaboration with Helmholtz Zentrum München & Medigene – March 2020 ‣ IND enabling study results for PH-762 – 2020 ‣ PH-762 (ACT – Melanoma with partner) into clinic – 2H:20 ‣ PH-762 (IT – Melanoma) – 2021 ‣ PH-804 (ACT – with